For the year ended March 31, 2024, the consolidated revenue stood at Rs 16,546 crore up by 3.5% over the previous year and the operating profit stood at Rs 2,869 crore growing by 10.1%, which was 17.3% of the sales.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi’s lab will be releasing their March quarter